Lucitanib

Cat. No.: OB0225WX-2254

Appearance: Solid

Purity: ≥96%

Identity: Confirmed by NMR, and LC-MS.

Size:

INQUIRY Datasheet MSDS

Add to basket

Product Overview

Description: Lucitanib is a potent multi-kinase inhibitor targeting VEGFR1/2/3 and FGFR1/2 with high affinity, featuring IC50 values ranging from 7 nM to 82.5 nM.

Synonym: E-3810; 1058137-23-7; E-3810 amine; E-3810 free base; 6-((7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yl)oxy)-N-methyl-1-naphthamide; 6-[7-[(1-aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl]oxy-N-methylnaphthalene-1-carboxamide; CHEBI:65209; 6-({7-[(1-Aminocyclopropyl)methoxy]-6-Methoxyquinolin-4-Yl}oxy)-N-Methylnaphthalene-1-Carboxamide; 1-Naphthalenecarboxamide, 6-((7-((1-aminocyclopropyl)methoxy)-6-methoxy-4-quinolinyl)oxy)-n-methyl-; 6-({7-[(1-aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl}oxy)-N-methyl-1-naphthamide; 6-((7-((1-Aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yl)oxy)-n-methylnaphthalene-1-carboxamide; 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxy-quinolin-4-yloxy)-N-methyl-1-naphthamide

CAS No.: 1058137-23-7

Compound CID: 25031915

Formula: C₂₆H₂₅N₃O₄

Formula Weight: 443.49

Specification

Targets&IC50: VEGFR1: 7 nM; FGFR2: 82.5 nM; VEGFR2: 25 nM; VEGFR3: 10 nM; FGFR1: 17.5 nM

Relative Density: 1.285 g/cm³

Stability: 3 years in powder form.

Storage: Storage at -20°C.

Applications: Lucitanib is utilized in advanced oncology research as a potent multi-kinase inhibitor targeting VEGFR, FGFR, and PDGFR to investigate the disruption of tumor angiogenesis and growth signaling.